Developing a novel anti-leukemic therapy through the combination of proteasome inhibitors and chimeric antigen receptor (CAR) expressing natural killer cells

Documenti analoghi

• Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
  di: Sedloev, David, et al.
  Pubblicazione: (2024)
• Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies
  di: Wang, Sanmei, et al.
  Pubblicazione: (2021)
• Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
  di: Schubert, Maria-Luisa, et al.
  Pubblicazione: (2021)
• Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations
  di: Blüm, Philipp, et al.
  Pubblicazione: (2024)
• Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)
  di: Hofmann, Susanne, et al.
  Pubblicazione: (2019)